Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Mauro Chiarito, Davide Cao, Samantha Sartori, Zhongjie Zhang, Birgit Vogel, Alessandro Spirito, Kenneth F. Smith, William Weintraub, Craig Strauss, Catalin Toma, Anthony DeFranco, Mark B. Effron, Giulio Stefanini, Stuart Keller, Samir Kapadia, Sunil V. Rao, Timothy D. Henry, Stuart Pocock, Samin Sharma, George DangasAnnapoorna Kini, Usman Baber, Roxana Mehran

Research output: Contribution to journalArticlepeer-review

Abstract

Aims Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk Methods PROMETHEUS was a multicentre prospective study comparing prasugrel vs. clopidogrel in ACS patients undergoing per- and results cutaneous coronary intervention (PCI). Patients were at HTR if presenting with one clinical plus one procedural risk feature. The primary endpoint was major adverse cardiac events (MACE), composite of death, myocardial infarction, stroke, or unplanned revascularization, at 1 year. Adjusted hazard ratio (adjHR) and 95% confidence intervals (CIs) were calculated with propensity score stratification and multivariable Cox regression. Among 16 065 patients, 4293 (26.7%) were at HTR and 11 772 (73.3%) at low-to-moderate thrombotic risk. The HTR conferred increased incidence of MACE (23.3 vs. 13.6%, HR 1.85, 95% CI 1.71–2.00, P < 0.001) and its single components. Prasugrel was prescribed in patients with less comorbidities and risk factors and was associated with reduced risk of MACE (HTR: adjHR 0.83, 95% CI 0.68–1.02; low-to-moderate risk: adjHR 0.75, 95% CI 0.64–0.88; pinteraction = 0.32). Conclusion High thrombotic risk, as defined by the 2020 ESC NSTE-ACS guidelines, is highly prevalent among ACS patients undergoing PCI. The HTR definition had a strong prognostic impact, as it successfully identified patients at increased 1 year risk of ischaemic events.

Original languageEnglish
Pages (from-to)594-603
Number of pages10
JournalEuropean Heart Journal: Acute Cardiovascular Care
Volume12
Issue number9
DOIs
StatePublished - 1 Sep 2023

Fingerprint

Dive into the research topics of 'Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study'. Together they form a unique fingerprint.

Cite this